Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic
  • Search Hotels in Sunnyvale

  • ROOMS:

Arcturus Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 7, 2023

Arcturus to present at the Canaccord Genuity 43rd Annual Growth Conference, August 9, 2023

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will release its financial results for the quarter and six months ended June 30, 2023 after the market close on Monday, August 7th and will also host a conference call and webcast at 4:30 p.m. Eastern Time on August 7th, 2023.

The Company also announced it will present at the Canaccord Genuity 43rd Annual Growth Conference in Boston, on August 9, 2023, at 9:30 a.m. Eastern Time.

Arcturus Therapeutics Second Quarter 2023 Earnings Conference Call

  • Monday, August 7, 2023 @ 4:30 p.m. ET
  • Domestic: 1-877-407-0784
  • International: 1-201-689-8560
  • Conference ID: 13738872
  • Webcast: Link

Canaccord Genuity 43rd Annual Growth Conference

  • Wednesday, August 9, 2023 (9:30 a.m. ET)

A webcast and replay of the presentation will be available on the “Investor Relations/Events” section of the Company’s website at:

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (samRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase deficiency and cystic fibrosis, along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China, and other countries). For more information, visit In addition, please connect with us on Twitter and LinkedIn.

Arcturus Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 7, 2023


IR and Media Contacts

Arcturus Therapeutics

Neda Safarzadeh

VP, Head of IR/PR/Marketing

Kendall Investor Relations

Carlo Tanzi, Ph.D.

(617) 914-0008

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.